Author

Jeffrey Marchioni

The University of Texas at AustinORCID 0000-0001-7410-8653Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Organism:plant (other)· 1

Frequent Co-Authors

Jason J. LavinderiD· 3 shared Allison SeegeriD· 2 shared Douglas R. Townsend· 2 shared George GeorgiouiD· 2 shared Gregory C. IppolitoiD· 2 shared Jessica KainiD· 2 shared Sean A. Knudson· 2 shared Ana RodriguesiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Jason J. LavinderORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyDisease Models & MechanismsPeer-reviewedMay 1, 2026

The N-terminal region of malaria vaccine candidate Plasmodium falciparum asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies

Rolando Garza, Jeffrey Marchioni, Jared D. Honeycutt…·Evelien M. Bunnik

This study investigates B cell and antibody responses to PfARMA, finding that IgM and IgG predominantly target the N-terminal IDR1 region, but these responses do not correlate with protection against malaria.

1 citationtop 5%

plant (other)proteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintDec 26, 2025

Synergistic non-neutralizing plasma antibodies to PfRH5 drive potent malaria parasite growth inhibition

Jeffrey Marchioni, Kirsty McHugh, Jordan R. Barrett…·Jason J. Lavinder

The paper identifies synergistic non-neutralizing antibodies against PfRH5 that enhance malaria parasite growth inhibition when combined with neutralizing antibodies.

DOI 10.64898/2025.12.24.696081

humanproteomics

𝕏 PostBluesky

ImmunologyCell Reports MedicinePeer-reviewedAug 1, 2024

Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination

William N. Voss, Michael L. Mallory, Patrick O. Byrne…·Gregory C. Ippolito

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

48 citationstop 1%

humanproteomics

𝕏 PostBluesky